ARTICLE | Company News
GenVec, Fuso Pharmaceutical Industries Ltd. deal
December 16, 2002 8:00 AM UTC
GNVC and Fuso partnered to develop a targeted cancer therapy based on the tumor necrosis factor alpha gene (TNF-alpha). Under the three-year deal, GNVC will have worldwide rights, excluding Japan, to...